» Articles » PMID: 20217279

Convergence of Amyloid-beta and Tau Pathologies on Mitochondria in Vivo

Overview
Journal Mol Neurobiol
Date 2010 Mar 11
PMID 20217279
Citations 77
Authors
Affiliations
Soon will be listed here.
Abstract

The histopathological characteristics of Alzheimer's disease (AD) are amyloid-beta (Abeta) containing plaques and neurofibrillary tangles (NFTs) as well as neuronal and synaptic loss. Until today, the underlying mechanisms of the interplay of plaques and tangles remained unresolved. There is increasing evidence that mitochondrial dysfunction might be a possible link, as revealed by studies in several APP and tau transgenic mouse models. Recently, we examined mitochondrial function in a novel triple transgenic mouse model (pR5/APP/PS2)--(triple)AD mice--that combines both pathologic features of the disease in brain. Using comparative, quantitative proteomics (iTRAQ) and mass spectroscopy, we found a massive deregulation of 24 proteins, of which one third were mitochondrial proteins mainly related to complexes I and IV of the oxidative phosphorylation system (OXPHOS). Remarkably, deregulation of complex I was related to tau, whereas deregulation of complex IV was Abeta dependent, both at the protein and activity levels. The (triple)AD mice showed synergistic effects of Abeta and tau already at the age of 8 months, resulting in a depolarized mitochondrial membrane potential. At 12 months, the strongest defects on OXPHOS, synthesis of ATP and reactive oxygen species, were exhibited in the (triple)AD mice, again emphasizing synergistic, age-associated effects of Abeta and tau in impairing mitochondria. This review highlights the convergence of Abeta and tau on mitochondria and establishes a molecular link in AD pathology in vivo.

Citing Articles

Mitochondrial dysfunction in Alzheimer's disease: a key frontier for future targeted therapies.

Wang S, Liao Z, Zhang Q, Han X, Liu C, Wang J Front Immunol. 2025; 15:1484373.

PMID: 39877373 PMC: 11772192. DOI: 10.3389/fimmu.2024.1484373.


Gene therapy in Aβ-induced cell and mouse models of Alzheimer's disease through compensating defective mitochondrial complex I function.

Li H, Chen Z, Shen Y, Xiong T, Chen A, Chen L J Transl Med. 2024; 22(1):760.

PMID: 39143479 PMC: 11323700. DOI: 10.1186/s12967-024-05571-3.


Exploring the Roles of Key Mediators IKBKE and HSPA1A in Alzheimer's Disease and Hepatocellular Carcinoma through Bioinformatics Analysis.

Wang Y, Yang Y, Liang C, Zhang H Int J Mol Sci. 2024; 25(13).

PMID: 39000042 PMC: 11241202. DOI: 10.3390/ijms25136934.


Protein Kinase C (PKC) in Neurological Health: Implications for Alzheimer's Disease and Chronic Alcohol Consumption.

Singh N, Nandy S, Jyoti A, Saxena J, Sharma A, Siddiqui A Brain Sci. 2024; 14(6).

PMID: 38928554 PMC: 11201589. DOI: 10.3390/brainsci14060554.


Mitochondria in Alzheimer's Disease Pathogenesis.

Reiss A, Gulkarov S, Jacob B, Srivastava A, Pinkhasov A, Gomolin I Life (Basel). 2024; 14(2).

PMID: 38398707 PMC: 10890468. DOI: 10.3390/life14020196.


References
1.
Anandatheerthavarada H, Biswas G, Robin M, Avadhani N . Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol. 2003; 161(1):41-54. PMC: 2172865. DOI: 10.1083/jcb.200207030. View

2.
Hauptmann S, Scherping I, Drose S, Brandt U, Schulz K, Jendrach M . Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging. 2008; 30(10):1574-86. DOI: 10.1016/j.neurobiolaging.2007.12.005. View

3.
Yao Z, Drieu K, Papadopoulos V . The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001; 889(1-2):181-90. DOI: 10.1016/s0006-8993(00)03131-0. View

4.
Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig M, Radde R, Staufenbiel M . Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol. 2007; 171(6):2012-20. PMC: 2111123. DOI: 10.2353/ajpath.2007.070403. View

5.
Boutajangout A, Authelet M, Blanchard V, Touchet N, Tremp G, Pradier L . Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol Dis. 2004; 15(1):47-60. DOI: 10.1016/j.nbd.2003.09.007. View